The complaint was filled by shareholders who purchased securities between June 7, 2016 and Nov. 7, 2016. According to the suit, Zimmer Biomet misled the general and investing public regarding quality control issues.
An internal audit found Zimmer Biomet’s headquarters in Warsaw misled the public about its products and production.
Zimmer Biomet filed a motion to dismiss the complaint. However, a judge denied the device company’s request Sept. 26.
More articles on devices and implants:
Catalyst OrthoScience releases 3-peg glenoid implant for CSR Total Shoulder System: 4 notes
SpineGuard reports 5% revenue growth in Q3, 200 smart screw surgeries: 5 things to know
Spinal implants & surgical devices market to reach $21B by 2025: 4 highlights
